{"id":4752,"date":"2025-12-16T15:50:23","date_gmt":"2025-12-16T07:50:23","guid":{"rendered":"https:\/\/credevo.com\/s\/?page_id=4752"},"modified":"2025-12-26T13:30:39","modified_gmt":"2025-12-26T05:30:39","slug":"bioequivalence-study-protocol-catalogue","status":"publish","type":"page","link":"https:\/\/credevo.com\/s\/bioequivalence-study-protocol-catalogue\/","title":{"rendered":"Bioequivalence Study Protocols Catalogue"},"content":{"rendered":"\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"has-text-align-center has-medium-font-size\">Browse our complete library of scientifically validated, execution ready bioequivalence study  protocols for small-molecule generics. Developed in alignment with current <strong><a href=\"https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioequivalence-studies-pharmacokinetic-endpoints-drugs-submitted-under-abbreviated-new-drug\" target=\"_blank\" rel=\"noreferrer noopener\">FDA<\/a> and <a href=\"https:\/\/www.ema.europa.eu\/en\/ich-guideline-m13a-bioequivalence-immediate-release-solid-oral-dosage-forms-scientific-guideline#:~:text=26\/02\/2025-,Document%20history,release%20solid%20oral%20dosage%20forms\">EMA <\/a>bioequivalence guidance<\/strong>, with each protocol individually assessed and customized on a <strong>product-by-product basis<\/strong><\/p>\n<\/blockquote>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<div class=\"wp-block-media-text is-stacked-on-mobile\"><figure class=\"wp-block-media-text__media\"><img loading=\"lazy\" decoding=\"async\" width=\"1409\" height=\"2000\" src=\"https:\/\/credevo.com\/s\/wp-content\/uploads\/2025\/12\/Brivaracetam-BE-Protocol-Cover-Page-Credevo-1.png\" alt=\"Brivaracetam Bioequivalence Study Protocol Cover Page Credevo \" class=\"wp-image-4904 size-full\"\/><\/figure><div class=\"wp-block-media-text__content\">\n<p>CNS \/ Neurology<\/p>\n\n\n\n<p><strong>Brivaracetam<\/strong> Bioequivalence Study Protocol<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--1\"><a class=\"wp-block-button__link has-white-color has-cool-to-warm-spectrum-gradient-background has-text-color has-background has-link-color wp-element-button\" href=\"https:\/\/credevo.com\/s\/brivaracetam-bioequivalence-study-protocol\/\" target=\"_blank\" rel=\"noreferrer noopener\">View Protocol<\/a><\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-media-text is-stacked-on-mobile\"><figure class=\"wp-block-media-text__media\"><img loading=\"lazy\" decoding=\"async\" width=\"1409\" height=\"2000\" src=\"https:\/\/credevo.com\/s\/wp-content\/uploads\/2025\/12\/Emtricitabine-Tenofovir-BE-Protocol-Cover-Page-Credevo.png\" alt=\"Emtricitabine Tenofovir Bioequivalence Study Protocol Cover Page Credevo \" class=\"wp-image-4905 size-full\"\/><\/figure><div class=\"wp-block-media-text__content\">\n<p>Infectious Disease<\/p>\n\n\n\n<p><strong>Emtricitabine \/ Tenofovir<\/strong> Bioequivalence Study Protocol<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--2\"><a class=\"wp-block-button__link has-white-color has-cool-to-warm-spectrum-gradient-background has-text-color has-background has-link-color wp-element-button\" href=\"https:\/\/credevo.com\/s\/emtricitabine-tenofovir-alafenamide-bioequivalence-study-protocol\/\" target=\"_blank\" rel=\"noreferrer noopener\">View Protocol<\/a><\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-media-text is-stacked-on-mobile\"><figure class=\"wp-block-media-text__media\"><img loading=\"lazy\" decoding=\"async\" width=\"1409\" height=\"2000\" src=\"https:\/\/credevo.com\/s\/wp-content\/uploads\/2025\/12\/Tapentadol-Hydrochloride-BE-Protocol-Cover-Page-Credevo.png\" alt=\"Tapentadol Hydrochloride Bioequivalence Study Protocol Cover Page Credevo \" class=\"wp-image-4912 size-full\"\/><\/figure><div class=\"wp-block-media-text__content\">\n<p>Pain Management<\/p>\n\n\n\n<p><strong>Tapentadol Hydrochloride<\/strong> Bioequivalence Study Protocol<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--3\"><a class=\"wp-block-button__link has-white-color has-cool-to-warm-spectrum-gradient-background has-text-color has-background has-link-color wp-element-button\" href=\"https:\/\/credevo.com\/s\/tapentadol-hydrochloride-bioequivalence-study-protocol\/\" target=\"_blank\" rel=\"noreferrer noopener\">View Protocol<\/a><\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-media-text is-stacked-on-mobile\"><figure class=\"wp-block-media-text__media\"><img loading=\"lazy\" decoding=\"async\" width=\"1409\" height=\"2000\" src=\"https:\/\/credevo.com\/s\/wp-content\/uploads\/2025\/12\/LURASIDONE-HYDROCHLORIDE-BE-Protocol-Cover-Page-Credevo.png\" alt=\"LURASIDONE HYDROCHLORIDE Bioequivalence Study Protocol Cover Page Credevo \" class=\"wp-image-4908 size-full\"\/><\/figure><div class=\"wp-block-media-text__content\">\n<p>CNS \/ Psychiatry<\/p>\n\n\n\n<p><strong><strong>Lurasidone Hydrochloride<\/strong> <\/strong>Bioequivalence Study Protocol<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--4\"><a class=\"wp-block-button__link has-white-color has-cool-to-warm-spectrum-gradient-background has-text-color has-background has-link-color wp-element-button\" href=\"https:\/\/credevo.com\/s\/lurasidone-hydrochloride-bioequivalence-study-protocol\/\" target=\"_blank\" rel=\"noreferrer noopener\">View Protocol<\/a><\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-media-text is-stacked-on-mobile\"><figure class=\"wp-block-media-text__media\"><img loading=\"lazy\" decoding=\"async\" width=\"1409\" height=\"2000\" src=\"https:\/\/credevo.com\/s\/wp-content\/uploads\/2025\/12\/Rivaroxaban-BE-Protocol-Cover-Page-Credevo-1.png\" alt=\"Rivaroxaban Bioequivalence Study Protocol Cover Page Credevo \" class=\"wp-image-4914 size-full\"\/><\/figure><div class=\"wp-block-media-text__content\">\n<p>Hematology<\/p>\n\n\n\n<p><strong>Rivaroxaban<\/strong> Bioequivalence Study Protocol<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--5\"><a class=\"wp-block-button__link has-white-color has-cool-to-warm-spectrum-gradient-background has-text-color has-background has-link-color wp-element-button\" href=\"https:\/\/credevo.com\/s\/rivaroxaban-bioequivalence-study-protocol\/\" target=\"_blank\" rel=\"noreferrer noopener\">View Protocol<\/a><\/div>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<div class=\"wp-block-media-text is-stacked-on-mobile\"><figure class=\"wp-block-media-text__media\"><img loading=\"lazy\" decoding=\"async\" width=\"1409\" height=\"2000\" src=\"https:\/\/credevo.com\/s\/wp-content\/uploads\/2025\/12\/Ivabradine-BE-Protocol-Cover-Page-Credevo-1.png\" alt=\"Ivabradine Bioequivalence Study Protocol Cover Page Credevo \" class=\"wp-image-5371 size-full\"\/><\/figure><div class=\"wp-block-media-text__content\">\n<p>Cardiology<\/p>\n\n\n\n<p><strong>Ivabradine<\/strong> <strong>Hydrochloride<\/strong> Bioequivalence Study Protocol<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--6\"><a class=\"wp-block-button__link has-white-color has-cool-to-warm-spectrum-gradient-background has-text-color has-background has-link-color wp-element-button\" href=\"https:\/\/credevo.com\/s\/ivabradine-hydrochloride-bioequivalence-study-protocol\/\" target=\"_blank\" rel=\"noreferrer noopener\">View Protocol<\/a><\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-media-text is-stacked-on-mobile\"><figure class=\"wp-block-media-text__media\"><img loading=\"lazy\" decoding=\"async\" width=\"1409\" height=\"2000\" src=\"https:\/\/credevo.com\/s\/wp-content\/uploads\/2025\/12\/SacubitrilValsartan-BE-Protocol-Cover-Page-Credevo.png\" alt=\"Sacubitril\/ Valsartan Bioequivalence Study Protocol Cover Page Credevo \" class=\"wp-image-4907 size-full\"\/><\/figure><div class=\"wp-block-media-text__content\">\n<p>Cardiology<\/p>\n\n\n\n<p><strong>Sacubitril \/ Valsartan<\/strong> Bioequivalence Study Protocol<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--7\"><a class=\"wp-block-button__link has-white-color has-cool-to-warm-spectrum-gradient-background has-text-color has-background has-link-color wp-element-button\" href=\"https:\/\/credevo.com\/s\/sacubitril-valsartan-bioequivalence-study-protocol\/\" target=\"_blank\" rel=\"noreferrer noopener\">View Protocol<\/a><\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-media-text is-stacked-on-mobile\"><figure class=\"wp-block-media-text__media\"><img loading=\"lazy\" decoding=\"async\" width=\"1409\" height=\"2000\" src=\"https:\/\/credevo.com\/s\/wp-content\/uploads\/2025\/12\/Lenvatinib-Mesylate-BE-Protocol-Cover-Page-Credevo.png\" alt=\"Lenvatinib Mesylate Bioequivalence Study Protocol Cover Page Credevo \" class=\"wp-image-4913 size-full\"\/><\/figure><div class=\"wp-block-media-text__content\">\n<p>Oncology<\/p>\n\n\n\n<p><strong>Lenvatinib<\/strong> <strong>Mesylate<\/strong> Bioequivalence Study Protocol<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--8\"><a class=\"wp-block-button__link has-white-color has-cool-to-warm-spectrum-gradient-background has-text-color has-background has-link-color wp-element-button\" href=\"https:\/\/credevo.com\/s\/lenvatinib-bioequivalence-study-protocol\/\" target=\"_blank\" rel=\"noreferrer noopener\">View Protocol<\/a><\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-media-text is-stacked-on-mobile\"><figure class=\"wp-block-media-text__media\"><img loading=\"lazy\" decoding=\"async\" width=\"1409\" height=\"2000\" src=\"https:\/\/credevo.com\/s\/wp-content\/uploads\/2025\/12\/Fostamatinib-Disodium-BE-Protocol-Cover-Page-Credevo.png\" alt=\"Fostamatinib Disodium Bioequivalence Study Protocol Cover Page Credevo \" class=\"wp-image-4911 size-full\"\/><\/figure><div class=\"wp-block-media-text__content\">\n<p>Immunology \/ Hematology<\/p>\n\n\n\n<p><strong>Fostamatinib Disodium<\/strong> Bioequivalence Study Protocol<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--9\"><a class=\"wp-block-button__link has-white-color has-cool-to-warm-spectrum-gradient-background has-text-color has-background has-link-color wp-element-button\" href=\"https:\/\/credevo.com\/s\/fostamatinib-disodium-bioequivalence-study-protocol\/\" target=\"_blank\" rel=\"noreferrer noopener\">View Protocol<\/a><\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-media-text is-stacked-on-mobile\"><figure class=\"wp-block-media-text__media\"><img loading=\"lazy\" decoding=\"async\" width=\"1409\" height=\"2000\" src=\"https:\/\/credevo.com\/s\/wp-content\/uploads\/2025\/12\/Tofacitinib-citraten-BE-Protocol-Cover-Page-Credevo.png\" alt=\"Tofacitinib Citrate Bioequivalence Study Protocol Cover Page Credevo \" class=\"wp-image-4910 size-full\"\/><\/figure><div class=\"wp-block-media-text__content\">\n<p>Immunology \/ Rheumatology<\/p>\n\n\n\n<p><strong>Tofacitinib citrate<\/strong> Bioequivalence Study Protocol<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--10\"><a class=\"wp-block-button__link has-white-color has-cool-to-warm-spectrum-gradient-background has-text-color has-background has-link-color wp-element-button\" href=\"https:\/\/credevo.com\/s\/tofacitinib-citrate-bioequivalence-study-protocol\/\" target=\"_blank\" rel=\"noreferrer noopener\">View Protocol<\/a><\/div>\n<\/div>\n<\/div><\/div>\n<\/div>\n<\/div>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-center\">Need a Protocol for a Different Molecule?<\/h2>\n\n\n\n<p class=\"has-text-align-left\">If you are planning a Bioequivalence Study for a molecule not listed in our catalogue, share the details below. Our team will review feasibility and get back to you on protocol availability, scope, and timelines.<\/p>\n\n\n<div class=\"wpforms-container wpforms-container-full custom-form-border\" id=\"wpforms-5751\"><form id=\"wpforms-form-5751\" class=\"wpforms-validate wpforms-form wpforms-ajax-form\" data-formid=\"5751\" method=\"post\" enctype=\"multipart\/form-data\" action=\"\/s\/wp-json\/wp\/v2\/pages\/4752\" data-token=\"b077e3241edebfba4083f6668f16474b\" data-token-time=\"1775981357\"><noscript class=\"wpforms-error-noscript\">Please enable JavaScript in your browser to complete this form.<\/noscript><div class=\"wpforms-field-container\"><div id=\"wpforms-5751-field_7-container\" class=\"wpforms-field wpforms-field-name\" data-field-id=\"7\"><label class=\"wpforms-field-label\" for=\"wpforms-5751-field_7\">Name of the molecule <span class=\"wpforms-required-label\">*<\/span><\/label><input type=\"text\" id=\"wpforms-5751-field_7\" class=\"wpforms-field-medium wpforms-field-required\" name=\"wpforms[fields][7]\" required><\/div><div id=\"wpforms-5751-field_0-container\" class=\"wpforms-field wpforms-field-name\" data-field-id=\"0\"><label class=\"wpforms-field-label\" for=\"wpforms-5751-field_0\">Full Name <span class=\"wpforms-required-label\">*<\/span><\/label><input type=\"text\" id=\"wpforms-5751-field_0\" class=\"wpforms-field-medium wpforms-field-required\" name=\"wpforms[fields][0]\" required><\/div><div id=\"wpforms-5751-field_8-container\" class=\"wpforms-field wpforms-field-name\" data-field-id=\"8\"><label class=\"wpforms-field-label\" for=\"wpforms-5751-field_8\">Organisation<\/label><input type=\"text\" id=\"wpforms-5751-field_8\" class=\"wpforms-field-medium\" name=\"wpforms[fields][8]\" ><\/div><div id=\"wpforms-5751-field_1-container\" class=\"wpforms-field wpforms-field-email\" data-field-id=\"1\"><label class=\"wpforms-field-label\" for=\"wpforms-5751-field_1\">Organisational Email <span class=\"wpforms-required-label\">*<\/span><\/label><input type=\"email\" id=\"wpforms-5751-field_1\" class=\"wpforms-field-small wpforms-field-required\" name=\"wpforms[fields][1]\" spellcheck=\"false\" required><\/div><\/div><!-- .wpforms-field-container --><div class=\"wpforms-recaptcha-container wpforms-is-recaptcha wpforms-is-recaptcha-type-v2\" ><div class=\"g-recaptcha\" data-sitekey=\"6LeaQRYTAAAAAPo7U8jnZJBUndxcS3f0E3Vijb2k\"><\/div><input type=\"text\" name=\"g-recaptcha-hidden\" class=\"wpforms-recaptcha-hidden\" style=\"position:absolute!important;clip:rect(0,0,0,0)!important;height:1px!important;width:1px!important;border:0!important;overflow:hidden!important;padding:0!important;margin:0!important;\" data-rule-recaptcha=\"1\"><\/div><div class=\"wpforms-submit-container\" ><input type=\"hidden\" name=\"wpforms[id]\" value=\"5751\"><input type=\"hidden\" name=\"page_title\" value=\"\"><input type=\"hidden\" name=\"page_url\" value=\"https:\/\/credevo.com\/s\/wp-json\/wp\/v2\/pages\/4752\"><input type=\"hidden\" name=\"url_referer\" value=\"\"><button type=\"submit\" name=\"wpforms[submit]\" id=\"wpforms-submit-5751\" class=\"wpforms-submit\" data-alt-text=\"Sending...\" data-submit-text=\"Submit Request\" aria-live=\"assertive\" value=\"wpforms-submit\">Submit Request<\/button><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/credevo.com\/s\/wp-content\/plugins\/wpforms\/assets\/images\/submit-spin.svg\" class=\"wpforms-submit-spinner\" style=\"display: none;\" width=\"26\" height=\"26\" alt=\"Loading\"><\/div><\/form><\/div>  <!-- .wpforms-container -->\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><\/p>\n\n\n\n<details class=\"wp-block-details is-layout-flow wp-block-details-is-layout-flow\"><summary>Read More<\/summary>\n<p>Explore our collection of ready-to-use bioequivalence study protocols designed to accelerate generic drug development. Each protocol meets <strong>FDA<\/strong> and <strong>EMA <\/strong>requirements with detailed study designs and methodologies tailored to specific molecules.<\/p>\n\n\n\n<p><strong>Brivaracetam<\/strong>: It is a second-generation antiepileptic drug approved for the treatment of partial-onset (focal) seizures. It is characterized by rapid absorption, linear pharmacokinetics, and a short elimination half-life, making it well-suited for single-dose crossover bioequivalence studies. Establishing bioequivalence is crucial for supporting generic development and expanding access to cost-effective treatment options. Our ready-to-use bioequivalence study protocol for brivaracetam is developed in alignment with <strong>FDA Product-Specific Guidance<\/strong>, <strong>ICH E6 (R3) GCP<\/strong>, and <strong>EMA<\/strong> requirements, providing a regulatory-ready study design with defined pharmacokinetic, statistical, and safety frameworks to support efficient <strong>ANDA<\/strong> and global generic submissions.<\/p>\n\n\n\n<p><strong>Ivabradine<\/strong> <strong>Hydrochloride<\/strong>: It is a selective heart rate-lowering agent used to manage stable angina and chronic heart failure. Its predictable pharmacokinetics and well-understood safety profile make it an ideal candidate for bioequivalence studies, supporting the development of reliable generic alternatives. Our ready-to-use bioequivalence study protocol provides a fully <strong>regulator-aligned <\/strong>framework for study design, pharmacokinetic assessment, and safety monitoring, helping streamline study setup and accelerate regulatory submissions, ultimately supporting wider patient access to this important therapy.<\/p>\n\n\n\n<p><strong>Emtricitabine \/ Tenofovir<\/strong>: It is a widely used antiretroviral combination for HIV-1 treatment and PrEP, offering proven efficacy and improved renal and bone safety compared with older tenofovir formulations. With rapid absorption and predictable pharmacokinetics, it is well-suited for bioequivalence evaluation. Our ready-to-use bioequivalence study protocol offers a practical, <strong>regulator-ready<\/strong> roadmap for study design, pharmacokinetic assessment, and safety monitoring, designed to make study execution smoother and help bring safe, affordable generics to patients faster.<\/p>\n\n\n\n<p><strong>Sacubitril \/ Valsartan<\/strong>: It is a proven angiotensin receptor-neprilysin inhibitor (ARNI) used in chronic heart failure, combining sacubitril and valsartan to support heart function while reducing cardiovascular risk. Our ready-to-use bioequivalence study protocol offers a clear, practical framework for pharmacokinetic assessment, safety monitoring, and study execution, helping sponsors efficiently generate reliable <strong>BE data<\/strong>. By enabling accurate evaluation of absorption and exposure, the protocol supports regulatory submission and facilitates the development of affordable generic alternatives, ultimately improving patient access to this important therapy.<\/p>\n\n\n\n<p><strong>Tapentadol Hydrochloride<\/strong>: It is a centrally acting opioid analgesic indicated for the management of severe, persistent pain and neuropathic pain associated with diabetic peripheral neuropathy. Our <strong>ready-to-use<\/strong> bioequivalence study protocol provides a practical framework to assess the pharmacokinetics and safety of Tapentadol ER formulations, helping sponsors efficiently generate reliable BE data. By supporting precise evaluation of absorption and systemic exposure, the protocol facilitates regulatory submission and the development of safe, effective generic alternatives, ultimately improving access to pain management therapies while maintaining established safety standards.<\/p>\n\n\n\n<p><strong>Lenvatinib<\/strong> <strong>Mesylate<\/strong>: It is a multitargeted tyrosine kinase inhibitor used for the treatment of advanced cancers, including radioactive iodine-refractory differentiated thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and endometrial carcinoma. It works by selectively inhibiting VEGF receptors and other kinases, helping to slow tumor growth and progression. Our ready-to-use bioequivalence study protocol provides a structured framework to evaluate Lenvatinib\u2019s pharmacokinetics, leveraging its well-characterized absorption, high bioavailability, and relatively long half-life for precise and reliable <strong>PK assessment<\/strong>. By supporting efficient generation of BE data, the protocol helps facilitate <strong>regulatory submissions <\/strong>and the development of safe, effective generic alternatives, ultimately improving access to advanced oncology therapies.<\/p>\n\n\n\n<p><strong>Lurasidone<\/strong> <strong>Hydrochloride<\/strong>: It is an atypical antipsychotic approved for the treatment of schizophrenia and depressive episodes associated with Bipolar I Disorder in adults and adolescents. With a well-characterized pharmacokinetic profile, including moderate bioavailability enhanced by food and a half-life of approximately 18\u201320 hours, it offers predictable absorption and metabolism. Our <strong>ready-to-use bioequivalence study protocol<\/strong> is designed to generate <strong>robust PK data<\/strong> for generic development, supporting regulatory submissions and helping bring safe, effective alternatives to patients in need.<\/p>\n\n\n\n<p><strong>Fostamatinib<\/strong> <strong>Disodium<\/strong>: It is a spleen tyrosine kinase (Syk) inhibitor approved for the treatment of chronic immune thrombocytopenia (ITP) in adults who have not responded adequately to prior therapies. By targeting antibody-mediated platelet destruction, it offers a differentiated mechanism of action in a patient population with limited options. With predictable, linear pharmacokinetics and a well-defined safety profile, fostamatinib is well-suited for bioequivalence evaluation. Our ready-to-use BE study protocol is aligned with <strong>FDA guidance<\/strong>, focuses on the active metabolite R406, and supports efficient generic development while helping expand access to this important therapy for patients with refractory ITP.<\/p>\n\n\n\n<p><strong>Rivaroxaban<\/strong>: It is a direct factor Xa inhibitor widely used in the prevention and treatment of thromboembolic disorders, including stroke prevention and venous thromboembolism. The oral suspension formulation addresses important clinical needs in patients who have difficulty swallowing tablets, such as pediatric or dysphagic populations. With rapid absorption, predictable pharmacokinetics, and a <strong>well-established safety profile<\/strong>, rivaroxaban is well-suited for bioequivalence evaluation. Our ready-to-use BE study protocol is developed in line with current <strong>FDA guidance<\/strong>, incorporates an appropriate replicate design to address variability, and supports efficient generic development while helping expand access to flexible anticoagulant therapy options.<\/p>\n\n\n\n<p><strong>Tofacitinib<\/strong> <strong>Citrate<\/strong>: It is an orally administered Janus kinase (JAK) inhibitor approved for the treatment of rheumatoid arthritis and other immune-mediated inflammatory conditions in patients with an inadequate response to prior therapies. By offering an effective oral alternative to injectable biologics, it improves treatment convenience and flexibility. Tofacitinib has rapid absorption, a short half-life, and well-characterized pharmacokinetics, making it well-suited for bioequivalence evaluation. Our ready-to-use <strong>BE study protocol<\/strong> is developed in line with current <strong>FDA guidance<\/strong> and supports efficient generic development, helping broaden access to established targeted therapies in autoimmune disease management.<\/p>\n<\/details>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<p class=\"has-text-align-left\"> <a href=\"https:\/\/credevo.com\/s\/brivaracetam-bioequivalence-study-protocol\/\">Brivaracetam<\/a><\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<p class=\"has-text-align-center\"><a href=\"https:\/\/credevo.com\/s\/ivabradine-hydrochloride-bioequivalence-study-protocol\/\">Ivabradine Hydrochloride <\/a><\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<p class=\"has-text-align-right\"><a href=\"https:\/\/credevo.com\/s\/sacubitril-valsartan-bioequivalence-study-protocol\/\">Sacubitril\/Valsartan<\/a><\/p>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<p class=\"has-text-align-left\"><a href=\"https:\/\/credevo.com\/s\/emtricitabine-tenofovir-alafenamide-bioequivalence-study-protocol\/\" target=\"_blank\" rel=\"noreferrer noopener\">Emtricitabine\/Tenofovir<\/a><\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<p class=\"has-text-align-center\"><a href=\"https:\/\/credevo.com\/s\/rivaroxaban-bioequivalence-study-protocol\/\" target=\"_blank\" rel=\"noreferrer noopener\">Rivaroxaban<\/a><\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<p class=\"has-text-align-right\"><a href=\"https:\/\/credevo.com\/s\/fostamatinib-disodium-bioequivalence-study-protocol\/\" target=\"_blank\" rel=\"noreferrer noopener\">Fostamatinib Disodium<\/a><\/p>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<p class=\"has-text-align-left\"><a href=\"https:\/\/credevo.com\/s\/tapentadol-hydrochloride-bioequivalence-study-protocol\/\" target=\"_blank\" rel=\"noreferrer noopener\">Tapentadol Hydrochloride<\/a><\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<p class=\"has-text-align-center\"><a href=\"https:\/\/credevo.com\/s\/lurasidone-hydrochloride-bioequivalence-study-protocol\/\" target=\"_blank\" rel=\"noreferrer noopener\">Lurasidone Hydrochloride<\/a><\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<p class=\"has-text-align-right\"><a href=\"https:\/\/credevo.com\/s\/lenvatinib-bioequivalence-study-protocol\/\" target=\"_blank\" rel=\"noreferrer noopener\">Lenvatinib Mesylate<\/a><\/p>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<p class=\"has-text-align-left\"><a href=\"https:\/\/credevo.com\/s\/tofacitinib-citrate-bioequivalence-study-protocol\/\" target=\"_blank\" rel=\"noreferrer noopener\">Tofacitinib Citrate<\/a><\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\"><\/div>\n<\/div>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><a href=\"https:\/\/credevo.com\" target=\"_blank\" rel=\"noreferrer noopener\">Home<\/a> > Clinical Study Design > <a href=\"https:\/\/credevo.com\/s\/ready-to-use-bioequivalence-protocols-for-high-value-generics\/\" target=\"_blank\" rel=\"noreferrer noopener\">Ready-to-Use Bioequivalence Protocols for High-Value Generics<\/a> > <a href=\"https:\/\/credevo.com\/s\/bioequivalence-study-protocol-catalogue\" target=\"_blank\" rel=\"noreferrer noopener\"><a href=\"https:\/\/credevo.com\/s\/bioequivalence-study-protocol-catalogue\/\">Bioequivalence Study Protocols<\/a><\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Browse our complete library of scientifically validated, execution ready bioequivalence study protocols for small-molecule generics. Developed in alignment with current FDA and EMA bioequivalence guidance, with each protocol individually assessed and customized on a product-by-product basis CNS \/ Neurology Brivaracetam Bioequivalence Study Protocol Infectious Disease Emtricitabine \/ Tenofovir Bioequivalence Study Protocol Pain Management Tapentadol Hydrochloride [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"full-width-with-Img.php","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-4752","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.3.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Bioequivalence Study Protocols Catalogue - Credevo<\/title>\n<meta name=\"description\" content=\"Browse the library of scientifically validated, study-ready bioequivalence study protocols for small-molecule generics.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/credevo.com\/s\/bioequivalence-study-protocol-catalogue\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bioequivalence Study Protocols Catalogue - Credevo\" \/>\n<meta property=\"og:description\" content=\"Browse the library of scientifically validated, study-ready bioequivalence study protocols for small-molecule generics.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/credevo.com\/s\/bioequivalence-study-protocol-catalogue\/\" \/>\n<meta property=\"og:site_name\" content=\"Credevo\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/credevo\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-26T05:30:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/credevo.com\/s\/wp-content\/uploads\/2025\/12\/Brivaracetam-BE-Protocol-Cover-Page-Credevo-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"908\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@gocredevo\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/credevo.com\/s\/bioequivalence-study-protocol-catalogue\/\",\"url\":\"https:\/\/credevo.com\/s\/bioequivalence-study-protocol-catalogue\/\",\"name\":\"Bioequivalence Study Protocols Catalogue - Credevo\",\"isPartOf\":{\"@id\":\"https:\/\/credevo.com\/s\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/credevo.com\/s\/bioequivalence-study-protocol-catalogue\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/credevo.com\/s\/bioequivalence-study-protocol-catalogue\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/credevo.com\/s\/wp-content\/uploads\/2025\/12\/Brivaracetam-BE-Protocol-Cover-Page-Credevo-1.png\",\"datePublished\":\"2025-12-16T07:50:23+00:00\",\"dateModified\":\"2025-12-26T05:30:39+00:00\",\"description\":\"Browse the library of scientifically validated, study-ready bioequivalence study protocols for small-molecule generics.\",\"breadcrumb\":{\"@id\":\"https:\/\/credevo.com\/s\/bioequivalence-study-protocol-catalogue\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/credevo.com\/s\/bioequivalence-study-protocol-catalogue\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/credevo.com\/s\/bioequivalence-study-protocol-catalogue\/#primaryimage\",\"url\":\"https:\/\/credevo.com\/s\/wp-content\/uploads\/2025\/12\/Brivaracetam-BE-Protocol-Cover-Page-Credevo-1.png\",\"contentUrl\":\"https:\/\/credevo.com\/s\/wp-content\/uploads\/2025\/12\/Brivaracetam-BE-Protocol-Cover-Page-Credevo-1.png\",\"width\":1409,\"height\":2000,\"caption\":\"Brivaracetam BE Protocol Cover Page Credevo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/credevo.com\/s\/bioequivalence-study-protocol-catalogue\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Services\",\"item\":\"https:\/\/credevo.com\/s\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bioequivalence Study Protocols Catalogue\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/credevo.com\/s\/#website\",\"url\":\"https:\/\/credevo.com\/s\/\",\"name\":\"Credevo\",\"description\":\"Healthcare Product Development from Clinical Development to Commercialization\",\"publisher\":{\"@id\":\"https:\/\/credevo.com\/s\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/credevo.com\/s\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/credevo.com\/s\/#organization\",\"name\":\"Credevo Pte. Ltd.\",\"url\":\"https:\/\/credevo.com\/s\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/credevo.com\/s\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/credevo.com\/s\/wp-content\/uploads\/2021\/02\/logo_bw2_old.png\",\"contentUrl\":\"https:\/\/credevo.com\/s\/wp-content\/uploads\/2021\/02\/logo_bw2_old.png\",\"width\":160,\"height\":160,\"caption\":\"Credevo Pte. Ltd.\"},\"image\":{\"@id\":\"https:\/\/credevo.com\/s\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/credevo\",\"https:\/\/x.com\/gocredevo\",\"https:\/\/www.instagram.com\/credevo_official\/\",\"https:\/\/www.linkedin.com\/company\/credevo\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bioequivalence Study Protocols Catalogue - Credevo","description":"Browse the library of scientifically validated, study-ready bioequivalence study protocols for small-molecule generics.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/credevo.com\/s\/bioequivalence-study-protocol-catalogue\/","og_locale":"en_US","og_type":"article","og_title":"Bioequivalence Study Protocols Catalogue - Credevo","og_description":"Browse the library of scientifically validated, study-ready bioequivalence study protocols for small-molecule generics.","og_url":"https:\/\/credevo.com\/s\/bioequivalence-study-protocol-catalogue\/","og_site_name":"Credevo","article_publisher":"https:\/\/www.facebook.com\/credevo","article_modified_time":"2025-12-26T05:30:39+00:00","og_image":[{"url":"https:\/\/credevo.com\/s\/wp-content\/uploads\/2025\/12\/Brivaracetam-BE-Protocol-Cover-Page-Credevo-1.png","width":640,"height":908,"type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@gocredevo","twitter_misc":{"Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/credevo.com\/s\/bioequivalence-study-protocol-catalogue\/","url":"https:\/\/credevo.com\/s\/bioequivalence-study-protocol-catalogue\/","name":"Bioequivalence Study Protocols Catalogue - Credevo","isPartOf":{"@id":"https:\/\/credevo.com\/s\/#website"},"primaryImageOfPage":{"@id":"https:\/\/credevo.com\/s\/bioequivalence-study-protocol-catalogue\/#primaryimage"},"image":{"@id":"https:\/\/credevo.com\/s\/bioequivalence-study-protocol-catalogue\/#primaryimage"},"thumbnailUrl":"https:\/\/credevo.com\/s\/wp-content\/uploads\/2025\/12\/Brivaracetam-BE-Protocol-Cover-Page-Credevo-1.png","datePublished":"2025-12-16T07:50:23+00:00","dateModified":"2025-12-26T05:30:39+00:00","description":"Browse the library of scientifically validated, study-ready bioequivalence study protocols for small-molecule generics.","breadcrumb":{"@id":"https:\/\/credevo.com\/s\/bioequivalence-study-protocol-catalogue\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/credevo.com\/s\/bioequivalence-study-protocol-catalogue\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/credevo.com\/s\/bioequivalence-study-protocol-catalogue\/#primaryimage","url":"https:\/\/credevo.com\/s\/wp-content\/uploads\/2025\/12\/Brivaracetam-BE-Protocol-Cover-Page-Credevo-1.png","contentUrl":"https:\/\/credevo.com\/s\/wp-content\/uploads\/2025\/12\/Brivaracetam-BE-Protocol-Cover-Page-Credevo-1.png","width":1409,"height":2000,"caption":"Brivaracetam BE Protocol Cover Page Credevo"},{"@type":"BreadcrumbList","@id":"https:\/\/credevo.com\/s\/bioequivalence-study-protocol-catalogue\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Services","item":"https:\/\/credevo.com\/s\/"},{"@type":"ListItem","position":2,"name":"Bioequivalence Study Protocols Catalogue"}]},{"@type":"WebSite","@id":"https:\/\/credevo.com\/s\/#website","url":"https:\/\/credevo.com\/s\/","name":"Credevo","description":"Healthcare Product Development from Clinical Development to Commercialization","publisher":{"@id":"https:\/\/credevo.com\/s\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/credevo.com\/s\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/credevo.com\/s\/#organization","name":"Credevo Pte. Ltd.","url":"https:\/\/credevo.com\/s\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/credevo.com\/s\/#\/schema\/logo\/image\/","url":"https:\/\/credevo.com\/s\/wp-content\/uploads\/2021\/02\/logo_bw2_old.png","contentUrl":"https:\/\/credevo.com\/s\/wp-content\/uploads\/2021\/02\/logo_bw2_old.png","width":160,"height":160,"caption":"Credevo Pte. Ltd."},"image":{"@id":"https:\/\/credevo.com\/s\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/credevo","https:\/\/x.com\/gocredevo","https:\/\/www.instagram.com\/credevo_official\/","https:\/\/www.linkedin.com\/company\/credevo"]}]}},"_links":{"self":[{"href":"https:\/\/credevo.com\/s\/wp-json\/wp\/v2\/pages\/4752","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/credevo.com\/s\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/credevo.com\/s\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/credevo.com\/s\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/credevo.com\/s\/wp-json\/wp\/v2\/comments?post=4752"}],"version-history":[{"count":67,"href":"https:\/\/credevo.com\/s\/wp-json\/wp\/v2\/pages\/4752\/revisions"}],"predecessor-version":[{"id":5876,"href":"https:\/\/credevo.com\/s\/wp-json\/wp\/v2\/pages\/4752\/revisions\/5876"}],"wp:attachment":[{"href":"https:\/\/credevo.com\/s\/wp-json\/wp\/v2\/media?parent=4752"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}